It is likely that Therasense is the main reason that supplemental examination filings are so low and may not ramp up any time in the near future. Eugene Perez and Chad Rink of Birch Stewart Kolasch & Birch report.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at firstname.lastname@example.org
Birch Stewart Kolasch & Birch, USPTO, US Patent and Trademark Office, patent, AIA, supplemental examination, Therasense